Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$40.49

-0.23 (-0.56%)

10:14
12/10/18
12/10
10:14
12/10/18
10:14

Biohaven's rimegepant 'definitively' safe, well tolerated, says Piper Jaffray

Biohaven Pharmaceutical this morning reported positive data from a 12-month safety study of 1,780 patients, which included regularly scheduled liver function tests, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The bottom line is that rimegepant now definitively appears to be a safe and well-tolerated treatment and that Biohaven has successfully engineered out the liver toxicity associated with the first generation oral calcitonin gene-related peptides, says the analyst. He adds rimegepant also demonstrated efficacy in prevention, which he thinks bodes well for the ongoing pivotal trial. Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical with a $65 price target.

BHVN Biohaven Pharmaceutical
$40.49

-0.23 (-0.56%)

12/03/18
PIPR
12/03/18
NO CHANGE
Target $65
PIPR
Overweight
Piper says buy Biohaven 'aggressively' after 'impressive' data
Biohaven Pharmaceutical (BHVN) this morning reported "impressive" topline data from the Phase III trial testing the Zydis orally dissolving tablet formulation of rimegepant, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The study not only achieved statistical significance on both co-primary endpoints, "but surprisingly" also demonstrated an "incredibly rapid" 15 minute onset of action, says the analyst. Further, he notes that Biohaven reported pooled safety data from what is now three Phase III rimegepant studies and that the candidate "continues to be safe and well tolerated" with no signal of liver toxicity. Van Buren believes the new data "definitely makes" rimegepant a superior product to Allergan's (AGN) ubrogepant and the "best-in-class" oral calcitonin gene-related peptide. He reiterates an Overweight rating on Biohaven with a $65 price target and recommends that investors buy the stock "aggressively."
11/29/18
PIPR
11/29/18
NO CHANGE
PIPR
Piper Jaffray says 'no good reason' for Biohaven pullback
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating on Biohaven after attending the company's R&D day and hosting a fireside chat and investor dinner with company management during the 30th Annual Piper Jaffray Healthcare Conference. The analyst noted that Biohaven shares have experienced a significant pullback, for which he believes there was "no good fundamental reason." Van Buren added that after this week, he has an even higher level on conviction in a "clean 12-month safety update and a successful Phase III ODT study... and therefore rimegepant's $1B+ potential."
11/27/18
CANT
11/27/18
NO CHANGE
Target $55
CANT
Overweight
Cantor reiterates $55 price target on Biohaven after R&D day
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Biohaven Pharmaceutical with a $55 price target after attending the company's R&D day. The event was an opportunity to see the breadth of the company's glutamate pipeline, which "is notably broad, but early," Duncan tells investors in a research note. The analyst sees investor focus shifting toward troriluzole and the glutamate platform pending "interpretable, positive data" out of ongoing clinical trials in two indications in 2019.
11/23/18
ADAM
11/23/18
NO CHANGE
Target $46
ADAM
Buy
Biohaven inaugural investor day can be stock moving event, says Canaccord
Canaccord analyst Suman Kulkarni believes the pipeline at Biohaven Pharmaceutical could generate significant value as he sees Biohaven being more than just a migraine drug stock. He believes investors will warm up to its central nervous platform and sees the company's inaugural investor day as both interesting and a stock moving event. Kulkarni reiterated his Buy rating and $46 price target on Biohaven Pharmaceutical shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.